Prostate cancer and markers of bone metabolism: Diagnostic, prognostic, and therapeutic implications

Eric C. Nelson; Christopher P Evans; Chong-Xian Pan; Primo N Lara

doi:10.1007/s00345-007-0186-3

Prostate cancer and markers of bone metabolism: Diagnostic, prognostic, and therapeutic implications

Eric C. Nelson, Christopher P Evans, Chong-Xian Pan, Primo N Lara

Research output: Contribution to journal › Article

5 Scopus citations

Abstract

Knowledge of bone metastases complicating advanced prostate cancer (CaP) is increasingly relevant in patient selection for novel therapies. Current nuclear bone scintigraphy imaging has limited specificity for prostate metastases. As serum bone markers do correlate with bony lesions, they may play multiple roles in patients with advanced CaP. Currently, these markers play a role in prognostic nomograms for CaP. Recent studies suggest an expanding role for bone markers in the diagnosis and selection of patients for novel therapies. In the future, therapeutic roles for some of these marker pathways will emerge, eventually allowing greater individualization of patient care.

Original language	English (US)
Pages (from-to)	393-399
Number of pages	7
Journal	World Journal of Urology
Volume	25
Issue number	4
DOIs	https://doi.org/10.1007/s00345-007-0186-3
State	Published - Aug 2007

Fingerprint

Keywords

Androgen-independent prostate cancer
Bone markers
Bone metastases
Osteoprotegerin
Prostate cancer

ASJC Scopus subject areas

Urology

Cite this

Nelson, E. C., Evans, C. P., Pan, C-X., & Lara, P. N. (2007). Prostate cancer and markers of bone metabolism: Diagnostic, prognostic, and therapeutic implications. World Journal of Urology, 25(4), 393-399. https://doi.org/10.1007/s00345-007-0186-3

@article{7b195e48ea2548d7a9905492e159e81e,

title = "Prostate cancer and markers of bone metabolism: Diagnostic, prognostic, and therapeutic implications",

abstract = "Knowledge of bone metastases complicating advanced prostate cancer (CaP) is increasingly relevant in patient selection for novel therapies. Current nuclear bone scintigraphy imaging has limited specificity for prostate metastases. As serum bone markers do correlate with bony lesions, they may play multiple roles in patients with advanced CaP. Currently, these markers play a role in prognostic nomograms for CaP. Recent studies suggest an expanding role for bone markers in the diagnosis and selection of patients for novel therapies. In the future, therapeutic roles for some of these marker pathways will emerge, eventually allowing greater individualization of patient care.",

keywords = "Androgen-independent prostate cancer, Bone markers, Bone metastases, Osteoprotegerin, Prostate cancer",

author = "Nelson, {Eric C.} and Evans, {Christopher P} and Chong-Xian Pan and Lara, {Primo N}",

year = "2007",

month = aug

doi = "10.1007/s00345-007-0186-3",

language = "English (US)",

volume = "25",

pages = "393--399",

journal = "World Journal of Urology",

issn = "0724-4983",

publisher = "Springer Verlag",

number = "4",

}

TY - JOUR

T1 - Prostate cancer and markers of bone metabolism

T2 - Diagnostic, prognostic, and therapeutic implications

AU - Nelson, Eric C.

AU - Evans, Christopher P

AU - Pan, Chong-Xian

AU - Lara, Primo N

PY - 2007/8

Y1 - 2007/8

N2 - Knowledge of bone metastases complicating advanced prostate cancer (CaP) is increasingly relevant in patient selection for novel therapies. Current nuclear bone scintigraphy imaging has limited specificity for prostate metastases. As serum bone markers do correlate with bony lesions, they may play multiple roles in patients with advanced CaP. Currently, these markers play a role in prognostic nomograms for CaP. Recent studies suggest an expanding role for bone markers in the diagnosis and selection of patients for novel therapies. In the future, therapeutic roles for some of these marker pathways will emerge, eventually allowing greater individualization of patient care.

AB - Knowledge of bone metastases complicating advanced prostate cancer (CaP) is increasingly relevant in patient selection for novel therapies. Current nuclear bone scintigraphy imaging has limited specificity for prostate metastases. As serum bone markers do correlate with bony lesions, they may play multiple roles in patients with advanced CaP. Currently, these markers play a role in prognostic nomograms for CaP. Recent studies suggest an expanding role for bone markers in the diagnosis and selection of patients for novel therapies. In the future, therapeutic roles for some of these marker pathways will emerge, eventually allowing greater individualization of patient care.

KW - Androgen-independent prostate cancer

KW - Bone markers

KW - Bone metastases

KW - Osteoprotegerin

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=34548175778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548175778&partnerID=8YFLogxK

U2 - 10.1007/s00345-007-0186-3

DO - 10.1007/s00345-007-0186-3

M3 - Article

C2 - 17562051

AN - SCOPUS:34548175778

VL - 25

SP - 393

EP - 399

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 4

ER -

Access to Document

10.1007/s00345-007-0186-3